Alkermes (ALKS) AGM 2025 summary

Opening remarks and agenda

• The meeting opened with introductions and a review of the agenda, focusing on the Vibrance-1 Phase II study results for alixorexton in narcolepsy type 1 (NT1).

• Forward-looking statements and associated risk factors were highlighted, with references to SEC filings for further details.

Financial performance review

• No financial performance data was discussed during the meeting.

Strategic initiatives and plans

• Plans to rapidly initiate a Phase III registrational program for alixorexton in NT1 were announced, leveraging Phase II data to inform dose selection.

• Ongoing and future studies include Vibrance-2 in narcolepsy type 2 (NT2) and Vibrance-3 in idiopathic hypersomnia, with top-line data expected later in the year and next year, respectively.

• Preparations for Phase III are underway, with a focus on dose flexibility and individualized patient needs.